NASDAQ:MTVA MetaVia Q2 2025 Earnings Report $1.49 +0.03 (+2.05%) Closing price 04:00 PM EasternExtended Trading$1.51 +0.02 (+1.34%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast MetaVia EPS ResultsActual EPS-$2.86Consensus EPS -$3.52Beat/MissBeat by +$0.66One Year Ago EPSN/AMetaVia Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMetaVia Announcement DetailsQuarterQ2 2025Date8/7/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time8:30AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) MetaVia Earnings HeadlinesHC Wainwright Issues Positive Forecast for MetaVia EarningsAugust 14 at 1:43 AM | americanbankingnews.comMTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726August 12 at 7:18 PM | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.August 14 at 1:00 AM | Porter & Company (Ad)MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 6, 2026 | prnewswire.comMetaVia (MTVA) to Post Quarterly Earnings on ThursdayAugust 5, 2026 | americanbankingnews.comMetaVia Inc.: MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of ObesityJuly 9, 2026 | finanznachrichten.deSee More MetaVia Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MetaVia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MetaVia and other key companies, straight to your email. Email Address About MetaViaMetaVia (NASDAQ:MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.View MetaVia ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
